Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2024

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial

Lancet 2024;403(10429):850–859 doi 10.1016/S0140-6736(23)02650-8

Rech J,

Hagen M,

Braun J,

Kiltz U,

Fleck M,

Voll R,

Thiel J,

Feist E,

Largo R,

This study by Rech, et al. shows that 6-month treatment with abatacept was associated with a decrease in MRI inflammation, clinical symptoms, and risk of RA development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase.

Keywords:

January 2023

Innocuité et efficacité du bimekizumab chez les patients atteints de spondylarthrite ankylosante active : Résultats à trois ans d'un essai contrôlé randomisé de phase IIb et de son étude de prolongation ouverte

Expert Opin Biol Ther. 2023 doi: 10.1080/14712598.2022.2156283

Braun J,

Kiltz U,

Baraliakos X

This review aimed to discuss the emerging agents for the treatment of axSpA.

Keywords:

Review

November 2022

Recommandations ASAS-EULAR pour la prise en charge de la spondylarthrite axiale : mise à jour 2022

Ann Rheum Dis 2022; online ahead of print doi:10.1136/ard-2022-223296

Kiltz U,

Molto A,

Proft F,

Zhao SS,

Ziade N,

van der Heijde D

Since the last update in 2016, more data have become available on existing treatment options for axSpA, and particularly on IL-17i. The increasing availability of more drugs and with different modes of action raises questions around their positioning in the treatment pathway. This review sought to update the 2016 recommendations with newly available evidence.

Keywords:

ASAS-EULAR

September 2022

Efficacité et sécurité du traitement par Ixekizumab chez les patients atteints de spondylarthrite axiale : résultats à deux ans de l'étude COAST

RMD Open. 2022 doi: 10.1136/rmdopen-2021-002165

Braun J,

Kiltz U,

Bolce R,

Lin CY,

This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.